Lowering Drug Prices by Once Again Putting Americans First
Executive Order 14273 aims to restore and expand Trump-era prescription drug pricing reforms, framing itself as a correction to what it characterizes as the Biden administration's reversal of previous progress. The order presents a narrative that the Trump administration's first term included "numerous significant actions" and "some of the most aggressive in recent history" to lower drug prices, while claiming the Biden administration "reversed, walked back, or neglected many of these initiatives." Particularly, it criticizes the Inflation Reduction Act's Medicare Drug Price Negotiation Program as "administratively complex and expensive" with "much lower savings than projected," and identifies a "pill penalty" that allegedly distorts pharmaceutical innovation away from small molecule drugs toward more expensive biologics.
The order establishes fourteen sections of directives aimed at reforming prescription drug pricing across multiple federal programs. Key mechanisms include: improving the Medicare Drug Price Negotiation Program (requiring new guidance within 60 days); developing recommendations to stabilize Medicare Part D premiums (within 180 days); implementing a new payment model for high-cost drugs not subject to negotiation (within 1 year); conducting a survey of hospital acquisition costs for outpatient drugs; conditioning health center grants on providing affordable insulin and epinephrine; streamlining drug importation programs; requiring pharmacy benefit manager fee disclosure regulations; and addressing anti-competitive behavior by manufacturers. The order specifically targets the "pill penalty" by directing the Secretary of Health and Human Services to work with Congress to align treatment of small molecule drugs with biologics.
Implementation responsibility falls primarily to the Secretary of Health and Human Services, with additional roles for the Commissioner of Food and Drugs, the Secretary of Labor, the Director of the Office of Management and Budget, and White House policy officials. The order establishes specific timelines ranging from 60 days to one year for various directives, with several 90-day and 180-day deadlines for reports, recommendations, and regulatory proposals. While characterizing its approach as restoration of previous policies, the order frames itself as necessary for significant systemic reform, arguing that the "American people deserve better" and that its implementation will result in "putting Americans first and making America healthy again." The order emphasizes its goal of addressing price disparities between U.S. patients and those in other countries, though most mechanisms focus on domestic policy levers rather than international pricing comparisons.